Skye Bioscience director granted 75,000 stock options
Skye Bioscience director Karen L. Smith received a grant of stock options covering 75,000 shares of Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Skye Bioscience director Karen L. Smith received a grant of stock options covering 75,000 shares of Common Stock. The options have an exercise price of $0.615 per share and expire on March 31, 2036. They vest in equal monthly installments over the one-year period beginning March 31, 2026. Following this grant, she holds 75,000 stock options directly.
Insider Trade Summary
Grant/Award: 75,000 shares
Grant/Award
1 txn
Insider
Smith Karen L.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 75,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 75,000 contracts (Direct)
Footnotes (1)
- F1. The stock option vests in equal monthly installments over the one year period beginning March 31, 2026.
Key Figures
Options granted: 75,000 options
Exercise price: $0.615 per share
Expiration date: March 31, 2036
+2 more
5 metrics
Options granted
75,000 options
Stock Option (Right to Buy) grant to director
Exercise price
$0.615 per share
Conversion or exercise price for the stock options
Expiration date
March 31, 2036
Option term end date for the grant
Underlying shares
75,000 shares
Common Stock underlying the stock options
Post-transaction options held
75,000 options
Total derivative holdings following the grant
Key Terms
Stock Option (Right to Buy), vests in equal monthly installments, Common Stock, exercise price, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
vests in equal monthly installments financial
"The stock option vests in equal monthly installments over the one year period"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"conversion_or_exercise_price: 0.6150"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-03-31T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Skye Bioscience (SKYE) director Karen L. Smith report on this Form 4?
Karen L. Smith reported receiving a grant of stock options for 75,000 shares of Skye Bioscience Common Stock. These options are compensation, not an open-market purchase or sale, and give her the right to buy shares at a fixed exercise price in the future.
What are the key terms of the 75,000 Skye Bioscience (SKYE) stock options granted?
The grant covers 75,000 stock options with an exercise price of $0.615 per share and an expiration date of March 31, 2036. Each option represents the right to buy one share of Skye Bioscience Common Stock if and when it becomes vested and is exercised.
How do the Skye Bioscience (SKYE) stock options granted to Karen L. Smith vest?
The stock options vest in equal monthly installments over one year, beginning March 31, 2026. This means a portion of the 75,000 options becomes exercisable each month over that year, aligning vesting with continued service during the vesting period.
How many Skye Bioscience (SKYE) options does Karen L. Smith hold after this transaction?
After the grant, Karen L. Smith holds 75,000 stock options directly. These options relate to Skye Bioscience Common Stock, have an exercise price of $0.615 per share, and expire on March 31, 2036, subject to their monthly vesting schedule starting in 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates